Slides
Page 1
N Nobel Biocare Ormco Kerr DTX STUDIO SPARK CLEAR ALIGNER SYSTEM IMPLANT DIRECT ALPHA Bio Metrex ②DEXIS #AlpHABio INFECTION PREVENTION OSTEOGENICS ORASCOPTIC SUPERICH VISUALIZATION Envista B DEXIS HE SAY Q2 2026 Results August 5 , 2026
Page 2
Forward looking statements/Non-GAAP financial measures FORWARD-LOOKING STATEMENTS Certain statements in this presentation are “forward-looking statements” within the meaning of the U.S. federal securities laws, including statements regarding future financial performance, and the objectives and expectations of management. Terminology such as “believe, ” “anticipate, ” “should, ” “could, ” “intend, ” “will, ” “plan, ” “expect, ” “estimate, ” “project, ” “target, ” “may, ” “possible, ” “potential, ” “forecast” and “positioned” and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to the risk factors described in our filings with the Securities and Exchange Commission, which include those in the most recent Form 10-K for FY 2025 and subsequent filings. Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Forward-looking statements contained herein speak only as of the date of this presentation. Except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. NON-GAAP MEASURES All "Adjusted" amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the Appendix to this presentation. We do not reconcile forward looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions, discontinued products, and any other potential adjustments which would be reflected in any forecasted GAAP measure. Second Quarter 2026 Earnings 2
Page 3
3 Agenda Paul Keel Opening Thoughts Eric Hammes Q2 Financials Paul Keel Closing Thoughts Q&A Second Quarter 2026 Earnings
Page 4
Q2 2026 Summary Dental markets remain resilient despite macro volatility 5.0% topline growth: positive across both reporting segments and all major geographies Margin expansion: Adjusted gross margins +70 bps and adjusted EBITDA margins +230 bps Strong profit growth: Adjusted EBITDA +28%, adjusted EPS +58% 158% free cash conversion and 2.4 million shares repurchased Second Quarter 2026 EarningsCore growth, adj. gross margin, adj. EBITDA, adj. EPS and free cash conversion are non- GAAP measures. See appendix for reconciliation. Raising FY 2026 guidance - Core Growth: 3.5 – 4.5%, aEBITDA growth: 11 – 14%, aEPS: $1.50 – 1.55 4
Page 5
Q2 Strategic and Operational Highlights 5 Second Quarter 2026 EarningsCore growth, adj. EBITDA and adj. EPS are non-GAAP measures. See appendix for reconciliation. • Growth driven by ~3% volume and ~2% price • Equipment & Consumables core growth 8.5%, Consumables and Diagnostics both up HSD • Specialty Products and Technologies core growth 3.1%, Spark up DD and Implants up LSD • Continued new product launches, notably in Orthodontics and Consumables GrowthOperationsPeople • Major customer events in North America, Europe, Asia, and Latin America • New Envista Turkey headquarters opened in Istanbul • Hosted more than 60 kaizen events across the organization • Sustained investment in our communities, helping >4,000 patients through multiple Envista Smile Project events around the world • Ongoing broad-based contributions from EBS • Good manufacturing productivity supporting 70 bps adjusted Gross Margin expansion • Continued SG&A productivity supporting 230 bps adjusted EBITDA Margin expansion • Tax rate reduction contributing toadditional growth in adjusted EPS
Page 6
Notable New Product Launches in Q2 2026 6 Second Quarter 2026 Earnings • Lightweight, ergonomic geometry • 360O rotatable tip • Strong beam uniformity at clinical distances • Multiple modes for clinical flexibility • Safety features protect patient and clinician • Extended digital bonding offering to cover entire bracket portfolio • Highly precise and customized bracket placement • Streamlined digital workflow • Platform growing DD • All-in-one bioceramic endodontic sealer compatible with all obturation techniques • Flexible ZenSave Tips reduce waste while improving access in complex anatomies • Creates antimicrobial alkaline environment DemiPro Curing Light Ormco Digital Bonding Expansion ZenSeal Pro
Page 7
Q2 2026 | Financial Metrics 7 Q2 2026 Q2 2025 vPY Revenue $ 731M $682M +$49M Core Sales Growth(%) 5.0% 5.6% -60 bps Adjusted Gross Margin 55.1% 54.4% +70 bps Adjusted EBITDA $108M $84M +$24M Adjusted EBITDA% 14.7% 12.4% +230 bps Adjusted Diluted EPS $0.41 $0.26 +$0.15 Free Cash Flow $105M $76M $29M Summary • 5.0% Core Growth o Growth in both reporting segments o Growth in all major geographies o Continued, broad-based price performance • Adj EBITDA grew 28%, Margin 14.7% (+230 bps) o Strong volume, price capture, and FX o Good return on commercial and R&D investments o G&A discipline while investing in growth • $0.41 adjusted EPS, +58% year-on-year • $105M FCF , +38% year-on-year Core growth, Adj. gross margin, Adj. EBITDA, Adj. EBITDA Margin, Adj. EPS, and Free Cash Flow are non- GAAP measures. See appendix for reconciliation. Second Quarter 2026 Earnings
Page 8
Q2 2026 | Reported Revenue 8 Second Quarter 2026 EarningsCore Growth is a non-GAAP measure. See appendix for reconciliation. Revenue +7.1% Core Growth +5.0% $17M $12M $11M $5M $4M Q2 2025 Volume Price FX Spark Deferral Acquisition Q2 2026 $682M $731M
Page 9
Q2 2026 | Adjusted EBITDA 9 Second Quarter 2026 EarningsAdj. EBITDA is a non-GAAP measure. See appendix for reconciliation. Adj. EBITDA +28% +1.5% +1.5% +1.0% +0.6% -0.7% -1.6%12.4% 14.7%Margin Rate $12M $12M $11M $5M Q2 2025 Price FX Volume & Mix Net Productivity -$5M Tariff Costs -$11M Investments Q2 2026 $84M $108M
Page 10
Q2 2026 | Specialty Products & Technologies Core Growth, adj. operating profit, and adj. operating profit m argin are non-GAAP measures. See appendix for reconciliation. 10Second Quarter 2026 Earnings • Spark grew DD (HSD excluding net deferral change) • Brackets & Wires declined against strong 2025 comp • Implants up LSD, with balanced growth globally Growth • Positive price capture in both Ortho and Implants • Continued investment in Commercial and R&D • Margin expansion in both Ortho and Implants Profit $69.3 $60.2 $471.0 $445.1 Revenue ($M) Adjusted Operating Profit ($M) Q2 2025 Q2 2026 Q2 2025 Q2 2026 14.7% Margin % 13.5% Core Growth % 3.1% 4.7%
Page 11
Q2 2026 | Equipment & Consumables 11Second Quarter 2026 Earnings • Consumables up HSD, across geographies • Diagnostics also up HSD, driven by continued share gains in North America Growth • Strong price and volume contributions • New product and commercialization investments • Year-on-year benefit from FX Profit Q2 2025 Q2 2026 Q2 2025 Q2 2026 Adjusted Operating Profit ($M) Revenue ($M) 20.0% $41.5 $51.8 Margin % 17.5% $259.5 $237.0 Core Growth % 8.5% 7.3% Core Growth, adj. operating profit, and adj. operating profit m argin are non-GAAP measures. See appendix for reconciliation.
Page 12
Capital Expenditure, net Operating Cash Flow Free Cash Flow $14.1M $119.2M $105.1M Q2 2026 $12.3M $88.7M $76.4M Q2 2025 12Free Cash Flow and Free Cash Conversion are non-GAAP measures. See appendix for reconciliation. Second Quarter 2026 Earnings • 158% FCF Conversion • Net Debt / Adj. EBITDA of ~0.7X • 2.4M shares repurchased in Q2 Q2 2026 Cash Flow
Page 13
Adj. EBITDA Growth Core Sales Growth Adj. EPS 7% to 13% 2% to 4% $1.35 to $1.45 13 These forward-looking estimates do not reflect future gains and charges that are inherently difficult to predict and estimate du e to their unknown timing, effect and/or significance, such as certain future gains or losses on the sale of investments, acquisition or divestiture- related gains or charges, discrete tax items and legal contingency provisions. Free Cash Conversion ~100% Second Quarter 2026 Earnings Updating FY 2026 Guidance Prior Updated 11% to 14% 3.5% to 4.5% $1.50 to $1.55 ~100%
Page 14
14 2026 Investor Day Thursday September 17 9:00 am to Noon EDT In-person and webcast Details at investors.envistaco.com
Page 15
Closing Thoughts 15Second Quarter 2026 Earnings • Sustained dental market resilience despite macro volatility • Continued broad-based growth across portfolio • Strong operating leverage converting top line growth into even faster earnings growth • Reinvesting a portion of our gains to support continued future success • Raising 2026 guidance
Page 16
Q&A 16 16 16
Page 17
Appendix Non-GAAP Reconciliations 17
Page 18
Reconciliations | Adjusted Gross Profit and Adjusted Gross Margin ($ in Millions) 18Second Quarter 2026 Earnings Three Months Ended Six Months Ended July 3, 2026 June 27, 2025 July 3, 2026 June 27, 2025 Gross Profit $ 407.0 $ 369.9 $ 797.1 $ 705.9 Restructuring costs and asset impairments A 7.3 0.3 10.4 2.2 Fair value adjustment of acquisition-related inventory B 0.5 1.0 0.9 1.4 Tariff refunds C (12.6) — (12.6) — Adjusted Gross Profit $ 402.2 $ 371.2 $ 795.8 $ 709.5 Gross Margin (Gross Profit / Sales) 55.7 % 54.2 % 55.5 % 54.3 % Adjusted Gross Margin (Adjusted Gross Profit / Sales) 55.1 % 54.4 % 55.4 % 54.6 %
Page 19
Reconciliations | Adjusted Operating Profit ($ in Millions) 19Second Quarter 2026 Earnings Three Months Ended Six Months Ended July 3, 2026 June 27, 2025 July 3, 2026 June 27, 2025 Consolidated Operating Profit $ 80.3 $ 46.3 $ 142.8 $ 85.3 Amortization of acquisition-related and other intangible assets 17.4 19.0 36.2 37.8 Restructuring costs and asset impairments A 8.9 4.7 16.3 16.1 Fair value adjustment of acquisition-related inventory B 0.5 1.0 0.9 1.4 Tariff refunds C (12.6) — (12.6) — Litigation settlement D — — — 0.8 Acquisition-related expenses E — 0.1 0.3 0.3 Adjusted Operating Profit $ 94.5 $ 71.1 $ 183.9 $ 141.7 Adjusted Operating Profit as a % of Sales 12.9 % 10.4 % 12.8 % 10.9 % Specialty Products & Technologies Operating Profit $ 60.1 $ 45.3 $ 106.6 $ 82.9 Amortization of acquisition-related and other intangible assets 15.3 14.8 30.9 29.4 Restructuring costs and asset impairments A 6.1 0.1 10.5 4.3 Tariff refunds C (12.2) — (12.2) — Adjusted Operating Profit $ 69.3 $ 60.2 $ 135.8 $ 116.6 Adjusted Operating Profit as a % of Sales 14.7 % 13.5 % 14.6 % 13.8 % Equipment & Consumables Operating Profit $ 45.9 $ 36.1 $ 92.7 $ 68.0 Amortization of acquisition-related and other intangible assets 2.1 4.2 5.3 8.4 Restructuring costs and asset impairments A 4.2 1.2 6.2 3.5 Tariff refunds C (0.4) — (0.4) — Litigation settlement D — — — 0.8 Adjusted Operating Profit $ 51.8 $ 41.5 $ 103.8 $ 80.7 Adjusted Operating Profit as a % of Sales 20.0 % 17.5 % 20.5 % 17.8 %
Page 20
Reconciliations | Adjusted Net Income ($ in Millions) 20Second Quarter 2026 Earnings Three Months Ended Six Months Ended July 3, 2026 June 27, 2025 July 3, 2026 June 27, 2025 Net Income $ 53.7 $ 26.4 $ 92.4 $ 44.4 Amortization of acquisition-related and other intangible assets 17.4 19.0 36.2 37.8 Restructuring costs and asset impairments A 8.9 4.7 16.3 16.1 Fair value adjustment of acquisition-related inventory B 0.5 1.0 0.9 1.4 Tariff refunds C (12.6) — (12.6) — Litigation settlement D — — — 0.8 Acquisition-related expenses E — 0.1 0.3 0.3 Loss on equity investments F — — 2.0 — Tax effect of adjustments reflected above G (2.8) (6.2) (10.6) (15.0) Discrete tax adjustments and other tax-related adjustments H 1.4 (1.3) 1.6 (0.6) Adjusted Net Income $ 66.5 $ 43.7 $ 126.5 $ 85.2
Page 21
Reconciliations | Adjusted Diluted Earnings Per Share 21Second Quarter 2026 Earnings Three Months Ended Six Months Ended July 3, 2026 June 27, 2025 July 3, 2026 June 27, 2025 Diluted Earnings Per Share $ 0.33 $ 0.16 $ 0.56 $ 0.26 Amortization of acquisition-related and other intangible assets 0.11 0.11 0.22 0.22 Restructuring costs and asset impairments A 0.05 0.03 0.10 0.09 Fair value adjustment of acquisition-related inventory B — 0.01 0.01 0.01 Tariff refunds C (0.08) — (0.08) — Litigation settlement D — — — 0.01 Acquisition-related expenses E — — — — Loss on equity investments F — — 0.01 — Tax effect of adjustments reflected above G (0.01) (0.04) (0.06) (0.09) Discrete tax adjustments and other tax-related adjustments H 0.01 (0.01) 0.01 — Adjusted Diluted Earnings Per Share $ 0.41 $ 0.26 $ 0.77 $ 0.50
Page 22
Reconciliations | Adjusted EBITDA ($ in Millions) 22Second Quarter 2026 Earnings Three Months Ended Six Months Ended July 3, 2026 June 27, 2025 July 3, 2026 June 27, 2025 Net Income $ 53.7 $ 26.4 $ 92.4 $ 44.4 Interest expense, net 8.7 8.0 16.1 17.3 Income tax expense 20.7 14.3 34.2 25.3 Depreciation 10.4 10.8 20.8 19.9 Amortization of acquisition-related and other intangible assets 17.4 19.0 36.2 37.8 Restructuring costs and asset impairments A 8.9 4.7 16.3 16.1 Fair value adjustment of acquisition-related inventory B 0.5 1.0 0.9 1.4 Tariff refunds C (12.6) — (12.6) — Litigation settlement D — — — 0.8 Acquisition-related expenses E — 0.1 0.3 0.3 Loss on equity investments F — — 2.0 — Adjusted EBITDA $ 107.7 $ 84.3 $ 206.6 $ 163.3 Adjusted EBITDA as a % of Sales 14.7 % 12.4 % 14.4 % 12.6 %
Page 23
Reconciliations | Core Sales Growth1 1 We use the term “core sales” to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the fir st anniversary of the acquisition (“acquisitions”), (2) sales from discontinued products and (3) the impact of currency translation. Sales from discontinued products includes major brands or products that Envista has m ade the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or develop ment of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period- to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period -to-period change in sales and (b) the period-to-period change in sales after applying current period foreign exchange rates to the prior year period. We use the term “core sales growth” to refer to the measure of comparing current period core sales with the corresponding period of the prior year 23 During the first quarter of 2026, we updated our methodology for how we calculate changes in the sales price from period to p eriod. Changes in sales prices are now calculated by comparing the current quarter sales prices to the full year sales price average from the prior year as it better reflects pricing trends over time. Second Quarter 2026 Earnings Consolidated % Change Three Month Period Ended July 3, 2026 vs. Comparable 2025 Period % Change Six Month Period Ended July 3, 2026 vs. Comparable 2025 Period Total sales growth 7.1 % 10.5 % Plus the impact of: Acquisitions (0.5) % (0.6) % Currency exchange rates (1.6) % (2.8) % Core Sales Growth 5.0 % 7.1 % Specialty Products & Technologies Total sales growth 5.8 % 9.9 % Plus the impact of: Acquisitions (0.8) % (0.9) % Currency exchange rates (1.9) % (3.4) % Core Sales Growth 3.1 % 5.6 % Equipment & Consumables Total sales growth 9.5 % 11.8 % Plus the impact of: Currency exchange rates (1.0) % (1.9) % Core Sales Growth 8.5 % 9.9 %
Page 24
Reconciliations | Free Cash Flow ($ in Millions) 24Second Quarter 2026 Earnings Three Months Ended Six Months Ended July 3, 2026 June 27, 2025 July 3, 2026 June 27, 2025 Net operating cash (used in) provided by operating activities $ 119.2 $ 88.7 $ 115.9 $ 89.0 Less: payments for additions to property, plant and equipment (capital expenditures) (14.9) (12.3) (27.4) (18.2) Plus: proceeds from sales of property, plant and equipment 0.8 — 0.9 0.5 Free Cash Flow (FCF) $ 105.1 $ 76.4 $ 89.4 $ 71.3 FCF to Adjusted Net Income Conversion Ratio 158.0 % 174.8 % 70.7 % 83.7 %
Page 25
NOTES TO RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED) 25Second Quarter 2026 Earnings A We exclude impairment of certain long-lived assets, executive transition costs, and cost incurred pursuant to discrete restructuring plans. B Represents the fair value adjustment related to inventory acquired in connection with acquisitions. C Represents the U.S. Supreme Court's ruling to refund tariffs imposed under the International Emergency Economic Powers Act. D Represents the settlement of certain litigation matters. E Represents acquisition-related transaction expenses and integration costs with respect to business combinations. F Represents losses on equity investments. G This line item represents the aggregate tax effect of all pretax adjustments reflected in the preceding line items of the table using each adjustment's applicable tax rate, including the effect of interim tax accounting requirements of Accounting Standards Codification Topic 740 Income Taxes. H Discrete tax matters primarily relate to excess tax benefits from stock-based compensation, changes in estimates associated with prior period uncertain tax positions and audit settlements, tax benefits resulting from a change in law, and changes in determination of realization of certain deferred tax assets.
Page 26
Statement Regarding Non-GAAP Measures 26Second Quarter 2026 Earnings Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Envista Holdings Corporation's (“Envista” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors to: • with respect to Core Sales, identify underlying growth trends in Envista’s business and compare Envista’s revenue performance with prior and future periods and to Envista’s peers; • with respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, understand the long-term profitability trends of Envista’s business and compare Envista’s profitability to prior and future periods and to Envista’s peers; • with respect to Adjusted EBITDA, help investors understand operational factors associated with Envista’s financial performance because it excludes the following from consideration: interest, taxes, depreciation, amortization, and infrequent or unusual losses or gains such as goodwill impairment charges or nonrecurring and restructuring charges. Management uses Adjusted EBITDA, as a supplemental measure for assessing operating performance in conjunction with related GAAP amounts. In addition, Adjusted EBITDA is used in connection with operating decisions, strategic planning, annual budgeting, evaluating Company performance and comparing operating results with historical periods and with industry peer companies; and • with respect to Free Cash Flow (the “FCF Measure”), understand Envista’s ability to generate cash without external financings, in order to invest and grow its business through acquisitions and other strategic opportunities. A limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures, and as a result the entire Free Cash Flow amount is not necessarily available for discretionary expenditures. Management uses these non-GAAP measures to evaluate the Company’s operating and financial performance. The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons: • With respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA: ◦ We exclude amortization of acquisition-related and other intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized. ◦ With respect to the other items excluded from Adjusted Gross Profit, Adjusted Net Income, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Envista's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. • With respect to core sales, we exclude (1) the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult, (2) sales from discontinued products because discontinued products do not have a continuing contribution to operations and management believes that excluding such items provides investors with a means of evaluating our on-going operations and facilitates comparisons to our peers, and (3) the impact of currency translation because it is not under management’s control, is subject to volatility and can obscure underlying business trends. • With respect to the FCF Measure, we adjust for payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to arrive at the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.